statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TimesSquare Capital Management LLC raised its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) by 1,270.7% in the 3rd quarter, according to the company in its most recent...

TimesSquare Capital Management LLC Has $23.44 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the...

MoonLake announces significant improvements with Nanobody  sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  Analysts at HC Wainwright raised their Q1 2024 earnings estimates for MoonLake Immunotherapeutics in a note issued to investors...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Forecasted to Earn Q1 2024 Earnings of ($0.30) Per Share

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  Stock analysts at Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for shares of MoonLake...

FY2028 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By Leerink Partnrs

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  HC Wainwright issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on...

HC Wainwright Weighs in on MoonLake Immunotherapeutics' Q1 2025 Earnings (NASDAQ:MLTX)

Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm...

Wedbush Reaffirms Outperform Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Invesco Ltd. lowered its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) by 4.4% in the third quarter, according to its most recent filing with the Securities and...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Invesco Ltd.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024...

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody  sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report)s stock had its buy rating reissued by equities researchers at Needham & Company LLC in a research report issued...

Needham & Company LLC Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report) shares shot up 7.6% during trading on Friday following a stronger than expected earnings report. The stock traded as high as $52.23...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.6% on Earnings Beat

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Watchers	531
52-Wk Low	$24.31
52-Wk High	$64.98

Volume	356,961.00
52-Wk High	$64.98
52-Wk Low	$24.31

MLTX MoonLake Immunotherapeutics - Ordinary Shares - Class A

About

Feed

News

Sentiment

Fundamentals